5 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 2 | Terminated 2 |
Follow Refractory Hairy Cell Leukemia: new trials by email Literature Review of Refractory Hairy Cell Leukemia trials Research Report on Refractory Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
Leukemia, Hairy Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Intraocular Lymphoma (3) · Leukemia, Large Granular Lymphocytic (3) · Lymphoma, T-Cell, Cutaneous (3) · Mycosis Fungoides (3)
Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Leukemia, B-Cell (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Rituximab (2) · Brentuximab Vedotin (1) · CTLA-4 Antigen (1) · Deferasirox (1) · Ipilimumab (1) · Lenalidomide (1) · Sunitinib (1)
National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Northwestern University (1)
United States (5)
Adam Petrich, MD (1) · Mohamed Sorror (1) · Srdan Verstovsek (1) · Stephen Ansell (1) · Vinod Pullarkat, MD (1)
N01CM62202 (1), P30CA015083 (1), P30CA015704 (1), U01CA069912 (1)